Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 3/20 | 0.37 |
| ▸ | MTOR | P42345 | 3/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | AKT2 | P31751 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 9/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 10/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 9/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 8/20 | 0.32 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | USP7 | Q93009 | 2/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11026169 | 0.76 | PIK3CA (0.37) | PIK3CAMTORAKT1AKT2PDE4A | |
| SCHEMBL752298 | 0.75 | USP7 (0.52) | PIK3CAMTORCCNE1CDK2USP7 | |
| SCHEMBL11032175 | 0.72 | PIK3CA (0.45) | PIK3CAMTORAKT1AKT2PDE4A | |
| SCHEMBL755266 | 0.69 | USP7 (0.38) | AKT1AKT2USP7 | |
| SCHEMBL17121438 | 0.67 | PDE4A (0.48) | PIK3CAMTORAKT1AKT2PDE4A | |
| SCHEMBL15308512 | 0.67 | PDE4A (0.41) | PIK3CAMTORAKT1AKT2PDE4A | |
| SCHEMBL1673128 | 0.64 | — | — | |
| SCHEMBL22858643 | 0.64 | PDE4A (0.44) | PIK3CAMTORPDE4APDE4BPDE4D | |
| SCHEMBL15306525 | 0.64 | PDE4A (0.35) | PIK3CAMTORAKT1AKT2PDE4A | |
| SCHEMBL4240536 | 0.63 | MAP4K4 (0.43) | AKT1AKT2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2430013-A1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | Amgen, Inc (US) | 2012-03-21 | — | — | EP | claimed |
| WO-2010132598-A1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC. (US) | 2010-11-18 | — | — | WO | claimed |
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | AMGEN INC. (US) | 2012-07-26 | — | — | US | disclosed |
| EP-2430013-A1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | Amgen, Inc (US) | 2012-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | PIK3CA, PIKFYVE, PIK3CD | PIK3CA 1/4885MTOR 21/4885AKT1 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.